bpc-157 adverse effects Should the FDA ease restrictions on compounded peptides? The debate is heating up. ⚠️ An FDA advisory panel is voting this week on whether to allow seven peptides—including TB-500 and BPC-157—to be bpc-157 adverse effects case report

The Unpublished Phase I Trial: A Critical Look A pivotal point of discussion is the Phase I clinical trial for BPC-157 in patients with IBD, registered on ClinicalTrials.gov

Weekly totals: GHK-Cu 12.5 mg, KPV 2.5 mg, BPC-157 2.5 mg, TB-500 2.5 mg

The overall appearance of density can increase even without dramatic new follicle activation, simply because existing follicles are producing healthier hair

Primary antibodies were used as follows: HIF-1 (ab6489, 1:1000, Abcam, Cambridge, MA, USA), HIF-2 (ab207607, 1:1000, Abcam), ALKBH5 (ab195377, 1:1000, Abcam), SOX2 (ab97959, 1:1000, Abcam), NANOG (ab109250, 1:1000, Abcam), ALDH1 (#36671, 1:1000, CST), E-cadherin (sc-21791, 1:1000, Santa Cruz), GAPDH (ab9485, 1:5000, Abcam) and ACTIN (AC026 1:5000, Abcam)